A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Clinical trial NCT05409482 · RECRUITING
Trial details
- NCT number
- NCT05409482
- Sponsor
- Meng Chao Hepatobiliary Hospital of Fujian Medical University
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-08-20
- Primary completion
- 2026-03-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.